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ABSTRACT
This study aims to evaluate drug utilization pattern, assess type II diabetes costs and their
relationship with patient characteristics, drug utilization pattern, self–care management, and
glycemic control. An observational follow–up study conducted for 6 months among 79 type II
diabetes patients, randomly selected at a tertiary care center in Ramallah, Palestine. Data on patient
characteristics, drug utilization pattern, self–care management and glycemic control were collected
from personal interview and medical records review. Data on costs was obtained from personal
interview in each visit. Statistical Package for Social Sciences (SPSS v 16.0) was used to perform a
descriptive, univariate, and multivariate analysis. The most common prescribed medications were
Biguanides, followed by Insulin. Approximately 59.5% of the participants received Statins, 49.4%
of them received Angiotensin–Converting Enzyme Inhibitors, 16.5% received oral hypoglycemic
drugs, 17.7% received Insulin, and 59.5% were on the combination treatment of oral hypoglycemic
drugs and Insulin. The mean ± SD medications number was 4.7 ± 2.2. The mean ± SD age of the
participants was 55.9 ± 8.4 years old. More than half of the participants were males (57.0%). The
estimated type II diabetes health care cost per 6 months of follow–up incurred by patients and
family members was Israeli Shekel 24,000 (US Dollar 6,480). Approximately 47.3% of the
participants followed a diabetic meal plan, 60.8% participated in physical exercise, 23.0% tested
their blood glucose level at home, and 78.1% were considered adherent with the Eight–Item
Morisky Medication Adherence Scale (MMAS–8) score ≥6. While only 21.9% had glycated
hemoglobin (HbA1c) level ≤7%. The medications number and Angiotensin–Converting Enzyme
Inhibitors were significantly related to health care cost. Type II diabetes costs were not
significantly related to self–care management and good glycemic control. This study reflects the
need for a more rational prescription mode in line with the patients’ health status, and provides a
useful platform for further pharmaco–economic research, meanwhile in reducing the costs incurred
by patients and family members, whereas it is obvious that the participants were low–income
patients.
Keywords: Self–care management, Drug utilization pattern, Cost, Palestine
INTRODUCTION
Diabetes is a common health problem
pertains medical consequences that are
translated into economic and social
consequences on individuals, national health
care providers and societies (1). The
worldwide diabetes prevalence was estimated
to be 6.4% in 2010 among adults aged 20 –
79 years old and will increase to 7.7% by
2030 (2). The estimated worldwide health
care expenditure on diabetes will be US

Dollar 396 billion by 2025 (3). The
developing countries accounted for the
largest share of this burden with 75% of these
estimates which could be attributed to aging
population,
unhealthy
diet,
obesity,
increasing urbanization, sedentary lifestyle,
and rapid social changes (3-6). The majority
of clinical studies addressing type II diabetes
characterization focused on developed
countries. Meanwhile, the Arab region in
general and Palestine in particular lack a
holistic research addressing type II diabetes
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management and health outcomes that
requires multi–modal and/or diverse health
care resources, along with effective health
care system collaboration (7, 8).
The glycemic control benefits are
evident. It was reported that every percentage
point drop in the glycated hemoglobin
(HbA1c) level, will result in reducing the
micro–vascular diabetic complications risk
by 40% (9). In contrast, patients with diabetic
complications have poor glycemic control
(HbA1c >7%), higher blood pressure, higher
serum
cholesterol
and
triglycerides
concentrations (10, 11). Most of the diabetes
health care cost is attributed to managing
diabetic complications especially when
hospitalization and inpatient health care is
needed. Moreover, transportation and
medication high costs were found to have a
significant relationship with patient self–care
management. Likewise, elevated health care
cost was a major factor related to poor
glycemic control (12). In conjunction,
patients are expected to play a major role in
order to achieve good glycemic control,
which
is
represented
by
self–care
management that is an essential component
of the World Health Organization (WHO)
and the Palestinian guidelines for type II
diabetes management (13, 14).
Glycemic control is believed to be
influenced by factors beyond the traditional
socio–demographic
and
clinical
characteristics. The majority of type II
diabetes patients require a long–term
administration of oral hypoglycemic drugs, to
ensure good glycemic control (10). In the
USA, 57% of type II diabetes patients were
treated with a mono–therapy of oral
hypoglycemic drugs, only 12% had a
combination treatment of oral hypoglycemic
drugs and Insulin, 8.6% of patients received
Insulin, while 15% neither took Insulin nor
oral hypoglycemic drugs (15). This suggests
that there is a complex model of socio–
demographic, clinical characteristics, drug
utilization pattern, self–care management,
and glycemic control that are related to costs.
The WHO has regulated the foundations
for diabetes management, and recommended
all ministries of health registered in the WHO
to implement its directions regarding early
and effective diabetes management and
diagnosis, and for patients to get an ideal

health care. Costs and effectiveness of
diabetes health care are a matter of foremost
consideration. Efficient resources utilization
is required. Several studies were carried out
in Palestine about diabetes. Unfortunately,
none of these studies assess the relationship
between factors such as drug utilization
pattern and costs. The oral hypoglycemic
drugs used to treat type II diabetes are Insulin
stimulators; they stimulate Insulin secretion
by β–cells, which in turn are subdivided into
Sulphonylureas and Non–Sulphonylureas
such as Glibenclamide and Repaglinide,
respectively. Insulin sensitizers increase
Insulin sensitivity and are subdivided into
Biguanides
(Metformin)
and
Thiazolidinediones. The available anti–
diabetic agents in the Palestinian Drug
Formulary are Insulin, Glibenclamide, and
Metformin as recommended by WHO (1619).
This study was conducted among
Palestinian type II diabetes patients in order
to evaluate drug utilization pattern of
different existing drug therapies, and assess
type II diabetes costs and their relationship
with patient characteristics, drug utilization
pattern, self–care management, and glycemic
control. The scarcity of research and data on
costs incurred by type II diabetes patients and
glycemic control in Palestine highlights the
importance of determining the expenditures
borne by patients and family members and
provides decision makers with necessary
information to further aid developing
personalized diabetes management and
control strategies.
METHODS
Study design
This was an observational follow–up
study conducted for 6 months among
Palestinian type II diabetes patients. The
study
adopted
the
prevalence–based
approach, which is useful for measuring the
economic burden of a disease for a given
time period. In the patient perspective, all
costs incurred by patients and family
members are included (20, 21). Costs on the
patients and the family members were
estimated in this study based on the co–
payments for insured patients and/or fees for
uninsured patients, and production losses.
The study used 2 data sources. One data
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source was a set of socio–demographic and
health information section, cost diary, and
self–care management scale which were
conducted via personal interview. The other
data source was the medical records, and co–
payment and/or fees lists (22).
Participants
This study employed patients who met
the sampling criteria from an accessible
population who visited the National Center
for Chronic Diseases and Dermatology
regularly and continuously in Ramallah,
Palestine. A tertiary care center affiliated to
the Palestinian Ministry of Health that
consists of several specialized sections,
including diabetes, which is a comprehensive
and integrated department serving diabetes
patients who were insured under the
government health insurance.
The target population was 1200 type II
diabetes patients. A minimum sample size is
calculated by Daniel formula based on that
there is no previous publications about good
glycemic control among Palestinian diabetes
patients and maximum good glycemic control
assumption rate in Palestine to be 50%.
Therefore, the total sample size was 292.
However, total target population is less than
10000, so adjusted sample size was
calculated from Daniel formula and an
estimated sample of 235 patients is
generated. The researcher recruited 247
patients in order to minimize erroneous
results and increase the study reliability.
However, the minimum sample size was re–
estimated to enroll minimum 20% of
calculated sample for an–observational
follow–up study to avoid bias sources such as
loss of individuals to follow–up during the
study (23, 24). Thus, a sample of 79 patients
was identified by simple random sampling.
The study included: 1) patients
diagnosed with type II diabetes; 2) with
available medical records; 3) received
ongoing anti–diabetic treatment; 4) currently
under active diabetes health care in the center
within the previous one year, and 5) willing
to participate in the study without physical
and/or mental conditions that could interfere
with their ability to complete data collection
requirements.
Data collection

This study was conducted at the first 6
months in a year, and was approved by
MARA University of Technology's Faculty
of Pharmacy Postgraduate Academic
Committee and Research Management
Institute and from the Palestinian Ministry of
Health. A personal interview was held to
collect data concerning age, gender,
occupation, additional chronic diseases, body
mass index, smoking status, and anti–diabetic
treatment modalities. Participants were asked
about their weight and height to calculate
their body mass index. Weight and height
were measured for participants who cannot
remember their weight and height while they
are wearing light clothes and taking the shoes
off. Body mass index was calculated as
weight in kilograms divided by height in
meter squared. Participants and researcher
were required to record resource use in a
detailed way to allow costs calculation by
multiplication with unit prices and/or unit
costs. During the follow–up time frame, each
participant attended personal interview at
every visit by using cost diary which is used
for covering each visit, and as a tool
contributing to assess costs of different kinds.
Follow–up participants were required to
record information concerning cost analysis
that cannot be obtained from the medical and
financial records (25, 26).
Direct medical costs are an impact of
diabetes health care on the health care
services use such as the general practice
visits, specialist care, lab tests, and unit
prices of medications doses (27). The cost
diary’s contribution in the direct medical
costs measurement is through the visits
number via personal interview at each visit to
the center; finding out who incurs the costs,
whether the participant or any of his/her
family members, friends, or others, and thus
the overall distribution costs; and medical
service/s received and thus confirmed or
denied copayments/fees payment (28, 29).
Data concerning direct non–medical costs
represented by transportation ways and costs
was collected. The participants were asked
about whether his/her visit was accompanied
by someone or alone, and with this part a
complete
calculation
of
the
total
transportation costs per visit according to the
transportation mode used to arrive at the
center could be made (30, 31). Time loss
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costs refer to calculating the number of
days/hours absent from paid and/or unpaid
work and days lost from housekeeping and
other daily activities mentioned by the
participants during each visit (21, 32, 33).
Based on their occupation, the participants
were asked about number of days and/or
hours that he/she took as leave, seeking to go
to the clinic. The same thing applied to
employed persons accompanying the
participant in order to be able to estimate
time lost costs per visit. Hence, total time
loss costs during the follow–up period were
calculated to get a complete picture of work
absence/normal activity lost days/hours of the
participants. Furthermore, the participant was
directed to indicate the arrival time to the
clinic, distance traveled and time needed to
arrive at the center. Health care cost was
estimated by collecting costs account for the
total direct medical costs; as well as total
direct non–medical costs and total time loss
costs.Self–care management dimensions
included diet, physical exercise, testing blood
glucose,
and
medication
adherence.
Medication adherence was measured using
the
Eight–Item
Morisky
Medication
Adherence Scale (MMAS–8) developed by
Professor Morisky (34, 35). This scale
consisted of eight items. The first seven items
are yes/no questions while last eighth
question is answered on a five point Likert
scale. Eight scores from the highest scores of
MMAS–8, so scores can range from zero to
eight. One score is given for each "No"
answer except for question number five
where one score is given for "Yes" answer. In
the eighth question, zero scores are given if
the answer is ticked on "all the time" item, in
contrast, to "never/rarely" answer where one
score is given. Therefore, the total MMAS–8
score is the sum–up of the scores for the eight
items. All available HbA1c last readings and
all the prescribed medications were
abstracted from medical records by medical
records checklist (36). Participants' responses
and medical records were treated with
confidentiality.
Operational definitions
Patient characteristics were categorized
as
socio–demographic
and
clinical
characteristics. Patient socio–demographic
characteristics included age, gender, and

occupation.
Whereas,
the
clinical
characteristics included the presence of
additional
chronic
diseases,
and
cardiovascular diseases risk factors that
included body mass index and smoking
status. Additional chronic diseases included
diabetic complications and non–diabetic
comorbidities, and additional chronic
diseases number. Body mass index was
categorized as normal if body mass index
was <25 kg/m², overweight if body mass
index was 25 – 29.9 kg/m², and obese if body
mass index was ≥30 kg/m² (37, 38).
Medication profile consisted of available
anti–diabetic agents in the Palestinian Drug
Formulary, antihypertensive medications,
Statins, and Aspirin. In addition, anti–
diabetic treatment modalities, Insulin
treatment regimen, and a medications number
were the main variables used for assessing
drug utilization pattern. A medications
number are the number of different
medications taken on a daily basis (39, 40).
Table 1 shows categories of acquired data
concerning medication treatment.
Table (1): Categories of Medication Profile
Item
Category
Metformin
Yes/No
Glibenclamide
Yes/No
Insulin
Yes/No
Antihypertensive
Yes/No
 ACEI
 Others
Yes/No
Statins
Yes/No
Aspirin
Yes/No
Anti–diabetic
treatment modalities
 Oral hypoglycemic
Yes/No
drugs
 Insulin
Yes/No
 Combined
oral
Yes/No
hypoglycemic
drugs and Insulin
Insulin
treatment
Insulin
regimen
Insulin + Metformin
Insulin + Metformin
Insulin + Metformin
+ Sulphonylurea
Medications number
≤3
4–6
≥7
Abbreviation:
ACEI
Enzyme Inhibitors.

Angiotensin–Converting

Follow a diabetic meal plan as
recommended by the dieticians for 3 days or
more in the previous 7 days means that the
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participants followed an eating plan as
recommended by the dieticians. Participants
who reported that they walked 3 days or
more in the previous 7 days were considered
as being engaged, at least 30 minutes in
physical exercise. Self–blood glucose
monitoring was defined for participants who
stated that they performed home glucose
monitoring for 5 days or more in the previous
7 days. The MMAS–8 score <6 reflected
medication non–adherence, while MMAS–8
score ≥6 reflected medication adherence. (41,
42). Glycemic control was analyzed by
determining the proportion of patients with
good glycemic control. Good glycemic
control refers to follow–up participants who
achieved HbA1c level ≤7% (43).
Statistical analysis
Statistical analysis was carried out using
Statistical Package for Social Sciences (SPSS
v 16.0). Mean ± SD health care cost was
calculated for subgroups of participants based
on categorical variables related to patient
characteristics and medication profile.
Intergroup differences in health care cost
were assessed for statistical significance
using multiple linear regressions. Binary
logistic regressions followed by multiple
logistic regressions were conducted to
determine type II diabetes costs that are
related to self–care management and good
glycemic control. A P value <0.05 was
considered statistically significant.
RESULTS
Participants’ characteristics
The study demonstrated that the mean ±
SD age was 56 ± 8.5 (median = 56; Q1 – Q3:
52 – 63). The age category of 48 – 57
accounted for the highest percentage
(39.2%). More than half of the participants
were
males
(57.0%).
Unemployed
participants divested the highest proportion
(35.4%). The mean ± SD additional chronic
diseases number was 3.3 ± 2.5 (median = 3;
Q1 – Q3: 1 – 5). The majority of the
participants had diabetic complications
(72.2%), and non–diabetic comorbidities
were found among 68.4% of the participants.
Less than half of the participants were obese
(45.6%), and more than one–third of them
were smokers (36.1%).

Drug utilization pattern
Metformin was the most frequently
prescribed (78.5%), followed by Insulin
(75.9%). About 48.1% of the participants
were on a mixture of Soluble and Isophane
Insulin. Statins ranked first among
medications for comorbidities (59.5%), while
Angiotensin–Converting Enzyme Inhibitors
(ACEI) and Aspirin ranked second (49.4%)
and third (45.6%), respectively among
medications for comorbidities. Details on all
prescribed medications are summarized in
Table 2. Combined oral hypoglycemic drugs
can be seen (i.e. Sulphonylureas +
Metformin). Only 17.7% of the participants
received Insulin, about 20.3% was receiving
oral hypoglycemic drugs, and more than half
of the participants received combination
treatment with oral hypoglycemic drugs and
Insulin (59.5%). In addition, the high
percentage of Insulin includes participants
who have been prescribed Insulin or in
combination with oral hypoglycemic drugs
(Table 3). The mean ± SD different
medications number taken on a daily basis
was 4.7 ± 2.2 (median = 5; Q1 – Q3: 3 – 6).
More than half of the participants took 4 to 6
medications on a regular basis (53.2%).
Table(2): Prescription Pattern of Drugs (N = 79)
Drug Category
Metformin
Sulphonylureas
Sulphonylureas +
Metformin
Insulin
Insulin Isophane
Human Soluble Insulin
Human Soluble +
Isophane Insulin
ACEI
Aspirin
Beta Blockers
Calcium Channel
Blockers
Angiotensin–II Receptor
Blocker
Diuretics
Statins
Antibiotics
Hematinic,
multivitamins
Omeprazole, Ranitidine
Antidepressants
Anticoagulants
Angina Pectoris
medications

Frequency (%)
62 (78.5)
15 (19.0)
7 (8.9)
60 (75.9)
11 (13.9)
11 (13.9)
38 (48.1)
39 (49.4)
36 (45.6)
17 (21.5)
23 (29.1)
4 (5.1)
19 (24.1)
47 (59.5)
3 (3.8)
15 (19.0)
13 (16.5)
15 (19.0)
7 (8.9)
5 (6.3)

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2017; 2(2): 93-112

98” ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــDrug utilization pattern and predictors ......”

Abbreviations: ACEI Angiotensin–Converting Enzyme
Inhibitors.

Table(3): Insulin Treatment Regimen (N = 60)
Treatment Type
Insulin
Insulin + Metformin
Insulin + Sulphonylureas
Insulin + Metformin +
Sulphonylureas

Frequency (%)
14 (23.3)
39 (65.0)
1 (1.7)
6 (10.0)

Type II diabetes costs

health care cost (mean ± SD = 313 ± 180).
The mean ± SD health care cost for the male
participants was 308 ± 183, which was found
to be higher than the same for female
participants which was 299.7 ± 114.4. In
addition, the highest health care cost was
found for those who stated that they were
employed (mean ± SD = 340.2 ± 195). There
was a significant difference in health care
cost among participants with different
additional chronic diseases numbers. The
highest health care cost found for the group
of participants with another 1 additional
chronic disease (Mean ± SD = 412.2 ±
210.9). A significant difference in health care
cost was found among participants who
received
ACEI
as
antihypertensive
medication. Subsequently, receiving ACEI
was significantly related to health care cost.
Furthermore, health care cost was found to
increase significantly and steadily with an
increasing medications number. The mean ±
SD health care cost for participants with a
number of medications 3 or less was 230.2 ±
145.6, while the same for those with the
number of medications 7 or more was 386.6
± 163.7 (Table 4).

The estimated health care cost incurred
by the participants and family members was
Israeli Shekel 24,000 (US Dollar 6,480) per 6
months of follow–up. Time loss costs
accounted the largest share (60.4%); about
25.2% was direct medical costs and 14.4%
was direct non–medical costs. Medication
costs accounted for 95.5% of the total direct
medical costs and 24.1% of health care cost,
respectively, while a percentage of lab tests
costs did not exceed 4.5% of the total direct
medical costs and 1.1% of health care cost,
respectively. The lowest health care cost was
found among the age group of 28 – 37 years
(mean ± SD = 283.9 ± 101) while the age
group of 48 – 57 years acquired the highest
Table (4): Health Care Cost for Different Categories (ILSª at 2014 Prices) (N = 79)
Variable
Age category
28 – 37
38 – 47
48 – 57
58 – 67
≥68
Gender
Male
Female
Occupation
Employed
Unemployed
Housewife
Diabetic complication
With
Without
Diabetic complications number
0
1
2
≥3

Frequency (%)

Health Care Cost
Mean ± SD

P–Value

3 (3.8)
9 (11.4)
31 (39.2)
28 (35.4)
8 (10.1)

283.9 ± 101.0
310.5 ± 175.3
313.0 ± 180.0
294.7 ± 149.9
306.3 ± 88.8

0.992

45 (57.0)
34 (43.0)

308.0 ± 183.0
299.7 ± 114.4

0.816

26 (32.9)
28 (35.4)
25 (31.6)

340.2 ± 195.0
267.6 ± 138.5
308.5 ± 123.5

0.233

57 (72.2)
22 (27.8)

286.7 ± 127.3
350.3 ± 211.0

0.106

22 (27.8)
14 (17.7)
17 (21.5)
26 (32.9)

350.3 ± 211.0
305.6 ± 120.7
278.3 ± 108.0
282.1 ± 144.9

0.414
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Non–diabetic comorbidities
With
Without
Non–diabetic comorbidities number
0
1
2
≥3
Additional chronic diseases number
0
1
2
3
≥4
Body mass index
Normal
Overweight
Obese
Smoking status
Smoker
Non–smoker
ACEI
Yes
No
Statins
Yes
No
Aspirin
Yes
No
Insulin duration
≤5
>5 and <10
≥10
Not taking Insulin
Anti–diabetic treatment modalities
Oral hypoglycemic drugs
Insulin
Combined oral hypoglycemic drugs
and Insulin
Anti–diabetic regimen
Metformin
Sulphonylureas + Metformin
Insulin
Insulin + Metformin
Insulin + Metformin + Sulphonylureas
Medications number
≤3
4–6
≥7

54 (68.4)
25 (31.6)

327.7 ± 149.6
254.3 ± 161.8

0.052

25 (31.6)
15 (19.0)
16 (20.3)
23 (29.1)

254.3 ± 161.8
341.7 ± 178.2
331.8 ± 152.8
315.6 ± 132.3

0.261

11 (13.9)
12 (15.2)
10 (12.7)
11 (13.9)
35 (44.3)

193.4 ± 74.4
412.2 ± 210.9
299.7 ± 153.5
330.4 ± 189.2
295.6 ± 122.1

0.016

8 (10.1)
29 (36.7)
36 (45.6)

300.8 ± 100.0
314.7 ± 196.6
312.3 ± 138.7

0.977

27 (34.2)
46 (58.2)

303.2 ± 166.3
317.1 ± 156.7

0.721

39 (49.4)
39 (49.4)

360.0 ± 173.1
249.4 ± 118.1

0.01

47 (59.5)
31 (39.2)

321.6 ± 154.2
279.1 ± 161.2

0.246

36 (45.6)
43 (54.4)

337.6 ± 148.0
279.3 ± 161.3

0.105

34 (43.0)
8 (10.1)
15 (19.0)
14 (17.7)

310.1 ± 153.2
284.9 ± 107.4
330.2 ± 175.5
278.3 ± 173.5

16 (20.3)
14 (17.7)
47 (59.5)

282.8 ± 160.7
289.6 ± 202.2
322.1 ± 141.7

0.616

9 (11.4)
7 (8.9)
14 (17.7)
39 (49.4)
7 (8.9)

298.8 ± 209.2
262.2 ± 73.1
289.6 ± 202.2
322.8 ± 133.0
339.3 ± 194.5

0.846

23 (29.1)
42 (53.2)
14 (17.7)

230.2 ± 145.6
317.7 ± 145.1
386.6 ± 163.7

0.008

0.815

Abbreviations: ILS Israeli Shekel; SD Standard deviation; ACEI Angiotensin–Converting Enzyme Inhibitors.
ª1 Israeli Shekel equals 0.27 US Dollar.
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Therefore, the medications number and
receiving ACEI accounted for 14.8% of the
health care cost variance. The largest
standardized coefficient (β) was for the
medications number, which was 0.261 (Table
5). Thus, the medications number made the
strongest unique contribution for explaining
health care cost variations.

Adjusting covariates using multiple
linear regressions found that medications
number and receiving ACEI are the variables
that were still significantly and independently
related to health care cost as shown in Table
5 (P <0.05). The sample multiple correlation
coefficients (R) of 2 variables and health care
cost was 0.425 and the adjusted R–square
was 0.148 (F (3,74) = 5.441, p <0.05).

Table (5): Multiple Linear Regression for Factors Related to Health Care Cost
Variable
Chronic diseases number
ACEI
Medications number

Standardized
Coefficients
(β)
–0.030
–0.259
0.261

Unstandardized
Coefficients
(B)
–3.141
–81.011
60.203

SE
11.740
35.649
27.514

T

P–Value

–0.268
–2.272
2.188

0.790
0.026
0.032

Abbreviation: SE Standard error; ACEI Angiotensin–Converting Enzyme Inhibitors.

Costs relating to self–care management
About 47.3% of participants followed a
diabetic meal plan as recommended by the
dietitians. More than half of the participants
participated in physical exercise (60.8%), and
only 23% of participants used to test their
blood–glucose levels at home. Most
participants were found to be medication
adherent (78.4%), and only 21.6% were non–
adherent. Univariate analysis (Table 6)
showed that there was a significant difference
between participants who followed a diabetic
meal plan as recommended by the dieticians
and those who did not follow in health care

cost and time loss costs. Subsequently,
participants who followed the dietitians’
diabetic meal plan had a significantly higher
health care cost and time loss costs ([O.R =
1.003; 95% C.I of 1.000 – 1.007] and [O.R =
1.004; 95% C.I of 1.000 – 1.008],
respectively). However, multivariate analysis
(Table 7) showed that there was no
significant difference between participants
who followed and those who did not follow a
diabetic meal plan as recommended by the
dieticians in health care cost and time loss
costs.

Table (6): Univariate Analysis of Costs Related to Follow a Diabetic Meal Plan
Cost

Health care
cost
Direct costs

Cost
Mean ± SD
or
Median
[Interquartile Range]
310.0 ± 151.5

Followed
(21.9%)

Did
not Odds Ratio P–Value
Follow
with 95%
(78.1%)
C.I

348.8 ± 155.2

275.2
± 1.003 (1.000
– 1.007)
141.1
112.9 ± 61.0 1.005 (0.997
– 1.012)
57.0 [39.0 – 1.01 (1.00 –
1.02)
109.0]
30.0 [18.0 – 1.01 (1.00 –
60.0]
1.02)

122.4 ± 67.0

132.9 ± 72.6

Direct medical
costs
Direct non–
medical costs

68.0 [41.5 – 111.8]

70.5 [48.5 –
125.0]
45.0 [18.0 –
72.0]

Time loss
costs

156.0 [104.0 – 224.7] 202.8 [124.8–
280.8]

35.0 [18.0 – 60.0]

145.6 [102.2 1.004 (1.000
– 187.2]
– 1.008)

0.043
0.204
0.317
0.321
0.008

Abbreviation: SD Standard deviation; C.I Confidence interval.
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Table (7): Multivariate Analysis of Costs Related to Follow a Diabetic Meal Plan
Cost
Health care
cost
Time loss costs

Coefficient
(β)
0.004

S.E

Wald

P–Value

1.107

Odds Ratio with 95%
C.I
1.004 (0.997–1.011)

0.004

0.000

0.004

0.019

0.999 (.0991–1.008)

0.890

0.293

Abbreviations: S.E Standard error; C.I Confidence interval.

those who did not (i.e. either never performed
Univariate analysis of type II diabetes
physical exercise or participated in physical
costs
related
to
physical
exercise
exercise but less than 30 minutes per day in
participation proved that there was no
the previous 7 days) in type II diabetes costs
significant difference between participants
(Table 8).
who participated in physical exercise and
Table (8): Univariate Analysis of Costs Related to Physical Exercise Participation
Cost

Heath
care cost
Direct
costs
Direct
medical
costs
Direct
non–
medical
costs
Time loss
costs

Cost
Mean ± SD
or
Median
[Interquartile Range]
299.8 [203.2
381.0]
122.4 ± 67.0

156.0
224.7]

[104.0

Did not
Participate
(39.2%)

Odds
Ratio P–
Value
with
95% C.I

– 301.4 [213.0
381.3]
119.8 ± 61.5

68.0 [41.5 – 111.8]
35.0 [18.0 – 60.0]

Participated
(60.8%)

– 290 [160.9 – 1.001 (0.998 – 0.412
368.4]
1.005)
126.5 ± 75.5
0.998 (0.992 – 0.673
1.005)
67.0 [44.0 – 121.0] 69.0 [36.0 – 1.003 (0.992 – 0.621
94.0]
1.014)
30.0 [15.0 – 60.0]

– 164.7 [129.9
246.0]

40.0 [21.8
65.0]

– 0.993 (0.982 – 0.238
1.004)

– 135.2 [86.1 – 1.002 (0.998 – 0.237
224.1]
1.007)

Abbreviation: SD Standard deviation; C.I Confidence interval.

Univariate analysis (Table 9) showed
that there was no significant difference
between participants who used to test their
blood glucose level at home and those who

did not test their blood glucose level at home
in type II diabetes costs.
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Table (9): Univariate Analysis of Costs Related to Testing Blood Glucose

Cost
Health care
cost
Direct costs
Direct
medical
costs
Direct non–
medical
costs
Time loss
costs

Cost
Mean ± SD
or
Median
[Interquartile Range]
299.8 [203.2 – 381.0]

Yes
(23%)

No
(77%)

Odds Ratio
with 95% C.I

301.4 [203.6 –
333.1]
124.3 ± 79.6

296.4 [200.7
– 381.3]
121.8 ± 63.5

0.379

68.0 [41.5 – 111.8]

60.0 [32.5 –
114.5]

69.0 [42.5 –
115.0]

0.998 (0.994 –
1.002)
1.001 (0.993 –
1.009)
0.999 (0.986 –
1.011)

35.0 [18.0 – 60.0]

40.0 [19.0 –
72.5]

35.0 [16.5 –
60.0]

1.003 (0.990 –
1.015)

0.674

156.0 [104.0 – 224.7]

135.2 [109.2 –
200.7]

156.0 [104.0
– 275.6]

1.6 (1.0 – 2.2)

0.268

122.0 ± 67.0

P–Value

0.892
0.846

Abbreviation: SD Standard deviation; C.I Confidence interval.

The univariate analysis results of type II
diabetes costs related to medication
adherence (Table 10) showed a lack of

significant difference between medications
adherers and non–adherers in type II diabetes
costs.

Table (10): Univariate Analysis of Costs Related to Medication Adherence
Cost
Health care
cost
Direct costs
Direct
medical
costs
Direct non–
medical
costs
Time loss
costs

Mean ± SD
or
Median
[Interquartile Range]
299.8 [203.2 – 381.0]
122.4 ± 67.0
68.0 [41.5 – 111.8]

Non–
Adherent
(21.6%)

Adherent
(78.4%)

Odds Ratio
with 95% C.I

P–Value

301.4 [207.6 – 290.6 [186.3 1.002 (0.998 – 0.284
390.5]
– 362.2]
1.006)
127.6 ± 69.1
103.7 ± 56.5 1.01 (1.00 – 0.209
1.02)
69.0 [42.3 – 62.0 [37.5 – 1.01 (1.00 – 0.324
121.3]
87.8]
1.02)

35.0 [18.0 – 60.0]

38.0[18.0
62.5]

– 21.0 [15.8 – 1.01 (1.00 – 0.330
55.0]
1.02)

156.0 [104.0 – 224.7]

156.0 [104.0 – 156.0 [106.6 1.002 (0.997 – 0.538
229.0]
– 230.9]
1.006)

Abbreviation: SD Standard deviation; C.I Confidence interval.

Costs relating to good glycemic control
The majority of the participants had poor
glycemic control (78.1%). Only 21.9% of the
participants achieved good glycemic control.
The univariate analysis results (Table 11)
showed a significant relationship between
good glycemic control and factors related to
total direct costs, both direct medical and
non–medical costs. So, increased total direct
costs, both medical and non–medical were

significantly related to decreased odds of
good glycemic control ([O.R = 0.979, 95%
C.I of 0.965 – 0.993] and [O.R = 0.978, 95%
C.I of 0.961 –0.996] and [O.R = 0.977, 95%
C.I of 0.956 – 0.999] respectively). In the
multivariate analysis (Table 12), there was
non–significant relationship between good
glycemic control and total direct costs, both
medical
and
non–medical
costs.
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Table (11):Univariate Analysis of Costs Related to Good Glycemic Control

Cost
Health care
cost
Total direct
costs
Direct
medical
costs
Direct non–
medical
costs
Time loss
costs

Cost
Mean ± SD
or
Median
[Interquartile Range]
297.2 ± 155.0
119.8 ± 67.9
69.0 [41.0 – 109.0]

Good
Glycemic
Control
(21.9%)

Poor
Glycemic
Control
(78.1%)

Odds Ratio
with 95% C.I

P–Value

241.3 ± 125.9

312.9
± 0.996 (0.992 – 0.108
159.7
1.001)
73.9 ± 36.5
132.7 ± 69.3 0.979 (0.965 – 0.004
0.993)
49.5 [29.6 – 70.0 [46.5 – 0.978 (0.961 – 0.018
71.3]
125.3]
0.996)

30.0[13.5 – 60.0]

16.5[1.5
29.6]

– 36.0[16.5
67.0]

– 0.977 (0.956 – 0.042
0.999)

156.0 [94.8 – 218.6]

156.0 [105.8 – 156.0 [93.6 – 0.999 (0.995 – 0.718
218.4]
227.8]
1.004)

Abbreviation: SD Standard deviation; C.I Confidence interval.

Table (12): Multivariate Analysis of Costs Related to Good Glycemic Control
Cost
Total direct costs
Direct medical costs

Coefficient (β)
–0.02
0.00

S.E
0.01
0.02

Wald
3.59
0.00

Odds Ratio with 95% C.I
0.98 (0.96 – 1.00)
1.00 (0.97 – 1.03)

P–Value
0.058
0.964

Abbreviations: S.E Standard error; C.I Confidence interval.

Discussion
The study found that Metformin was the
most frequently prescribed medication,
followed by Insulin, and the least was
Sulphonylureas, either as mono–therapy or in
combination with other oral hypoglycemic
drugs. This finding was inconsistent with
what is found in other studies (44, 45).
Sulphonylureas were the most frequently
prescribed oral hypoglycemic drugs in late
1990 (46). However, the prescribing pattern
orientation moved toward Metformin as the
most frequently prescribed oral anti–diabetic
agent, which is consistent with findings
reported by other studies (16, 19, 47-49).
Metformin is the first choice to start
treating type II diabetes patients along with
lifestyle recommendations in accordance to
what is recommended by WHO and
American Diabetes Association (ADA) to
start using Metformin concurrently with
lifestyle modification at the diagnosis time
due to its effectiveness, low costs, low side

effects incidence especially in terms of
hypoglycemia, its advantages in the patient's
lipid profile improvement, and diabetic
complications prevention. It reduces Insulin
resistance and might have a positive
influence on pancreatic β–cell (50-55). Both
Metformin and Sulphonylureas can be used
in combination with other oral hypoglycemic
drugs or Insulin (14, 51, 55). This study
found that Sulphonylureas were prescribed
for almost 19% of the participants and in
combination with Metformin for 8.9% of the
participants. Sulphonylureas remain second
main choice and best choice for combination
with Metformin as oral anti–diabetic agent
regardless of the rapid decrease in their
effectiveness over time (56). Therefore,
prescription of a combination of Metformin
and Sulphonylureas remains a common
practice (57).
Different Insulin types were prescribed
alone or in combination with oral
hypoglycemic drugs of different groups.
Failure of oral hypoglycemic drugs results in
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the Insulin use alone or in combination with
oral hypoglycemic drugs. This was reflected
in the results of the study shown to include
Insulin alone, in addition to Metformin;
Sulphonylureas;
and
Metformin
and
Sulphonylureas
together,
which
are
consistent with findings reported by other
studies (8, 58), but with different
percentages. The study results proved that
there is an increase in Insulin utilization
justified by oral hypoglycemic drugs
resistance and/or presence of comorbidities
(57). The combination of Insulin with
Metformin was most commonly prescribed
among the participants who were prescribed
Insulin. The combination of Insulin with
Metformin can cause liver sensitization to the
Insulin action which at least may have a
synergistic action in blood glucose level
control (59). Sulphonylureas use in
combination with Insulin can improve the
Insulin effectiveness in the type II diabetes
management after oral hypoglycemic drugs
secondary failure, which can improve blood
glucose levels and decrease the need for
Insulin (58, 59). The study results have
shown that Insulin use in addition to
Sulphonylureas and Metformin provides an
opportunity to take the Insulin use benefits in
combination with oral hypoglycemic drugs
(57, 59, 60).
Statins and Aspirin highlight the
multiple connotations linked to diabetic
complications
and
non–diabetic
comorbidities (56, 61, 62). Many studies
supported the fact that type II diabetes
patients are at risk of diabetic complications,
and cardiovascular diseases were the most
common comorbidities found in diabetic
patients, in which hypertension was the most
common, followed by hyperlipidemia (11,
63, 64). The ACEI role in cardiovascular
diseases prevention, suppression of the
progressive
development
of
diabetic
nephropathy and micro– and macro–vascular
diabetic complications with less health care
cost and more effectiveness might be a
justification for prescribing ACEI as a
principal strategy to increase patient’s
survival (65, 66). In addition, the study
results concerning ACEI prescription
reflected what is found in another study (67)
which reported that ACEI prescription
increased to 72%.

β–blockers prescription rates were the
lowest among the prescribed medications for
the participants. This reflects a growing
concern which tends toward β–blocker
underuse due to the fact that suggested β–
blockers avoidance especially non–selective
because of the probability of masking signs
and hypoglycemia symptoms (45, 56).
Further analysis of other drugs revealed
Aspirin prescription was 45.6%. This could
probably due to the fact documented by ADA
that Aspirin has the potential to be used as a
primary prevention strategy in diabetic
patients with cardiovascular diseases risk
factors including age 40 years and above,
obesity,
hypertension,
smoking,
dyslipidemia, albuminuria, and family history
(62, 68).
This study found that Statins were most
commonly prescribed medications for
additional
chronic
diseases.
High
dyslipidemia rates among diabetic patients
accounted for high mortality rate due to
cardiovascular diseases. Therefore, diabetes
is recognized as equivalent to cardiovascular
diseases
(69).
Subsequently,
WHO
guideline’s recommendation for diabetes
management is based on adding Statins in
addition to lifestyle modification irrespective
of lipid profile for diabetic patients (70).
Statins prescription among the participants is
justified. However, lack of Statins in every
prescription and/or among all the participants
might be due to either trial to avoid side
effect or drug–drug interactions or
participant's lipid profile was normal
regardless of physicians' awareness about the
WHO guideline. Also, interruption of some
medications varieties in the public clinics and
centers occasionally and considering
additional medications costs might be a
reason for not having Statins in every
prescription.
Furthermore, Aspirin is effective as
secondary prevention in a cardiovascular
morbidity and mortality reduction, which has
led to considerable interest in identifying
Aspirin as an effective mean for reduction of
cardiovascular diseases events and mortality
in diabetic patients (71). The Aspirin
prescription rate was higher in comparison
with previous reports which claimed that
13% of diabetic patients were treated with
Aspirin as a primary prevention (72, 73).
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Consequently, previous studies about the
Aspirin prescription in diabetic patients and
presence of hypertension and hyperlipidemia
among the participants have led to justifying
Aspirin prescription as primary and
secondary preventions.
This study demonstrated that the health
care cost constituted a major part of the
patients’ household monthly income. Most of
the estimated health care cost was
contributed by time loss costs. Conversely,
few studies have been done for diabetes costs
assessment in Palestine, despite the fact that
there is an urgent need for such studies
because of the delicate position in terms of
politics and economy thereto. Worsening of
glycemic control can lead to diabetic
complications
and
increased
costs.
Furthermore, the presence of non–diabetic
comorbidities, obesity, and smoking among
diabetic patients are potentially making
matters worse concerning health care cost,
which highlights the importance of improved
glycemic control and addressing other risk
factors (74, 75). Review of studies on
diabetes costs reported that there is a need for
studies on health care cost based on socio–
demographic and clinical characteristics of
diabetic patients in general and Palestine in
particular (76, 77). This study tried to add
some of what is new into cost assessment
areas. The univariate analysis showed that
there is no significant healthcare cost
difference among the participants’ socio–
demographic characteristics.
The univariate analysis found that the
additional chronic diseases number, ACEI
prescription, and the medications number
were found to be statistically significant.
However, the additional chronic diseases
number was excluded in multiple linear
regression. This implies the need for
addressing the additional chronic diseases
prevalence especially hypertension. No
laboratory tests were done to confirm the
diabetic complications and non–diabetic
comorbidities existence; they were detected
from both personal interview and medical
records review. The health care cost incurred
by those with diabetic complications was not
substantially higher than those without
diabetic complications. Thus, the likelihood
that the study failed to capture all diabetic
complications types increased. The health

care cost on patients with non–diabetic
comorbidities was higher than those without
non–diabetic comorbidities. However, there
is no progressive increase in health care cost
with
the
increased
non–diabetic
comorbidities number. The health care cost
also differs significantly from a medications
number and ACEI prescription pattern.
Therefore, the results showed that patients
with hypertension incurred the highest heath
care cost on the grounds that hypertension
prevalence was the highest, and on evidence
that multiple linear regression models
predicted that health care cost on patients
who were prescribed ACEI was found to
differ significantly.
This study considered type II diabetes
costs as factors for self–care management.
The univariate analyses showed a significant
relationship between health care cost, and
time loss costs and follow a diabetic meal
plan as recommended by the dieticians.
Therefore, participants who incurred high
health care cost and time loss costs were
more likely to follow a diabetic meal plan as
recommended by the dieticians. This
enhances the likelihood that diabetic meal
plan is a part of the expenses incurred by the
Palestinian patients and their family within
out of pocket expenditures. Consequently,
financial barriers mitigation by providing a
diabetic meal plan commensurate with the
income level may enhance follow a diabetic
meal plan, so that they were taken into
account although the multivariate analysis
proved a lack of significant relationship
between them and following dietician’s meal
plan. The findings have shown that type II
diabetes costs was not significantly related to
physical exercise participation, self–blood
glucose
monitoring,
and
medication
adherence, which are contrary to the vast
majority of studies (78-80). Other study
reported that high medication cost is the most
important reason for medication non–
adherence which is contrary to the study
findings (81). Furthermore, adequacy of
health care cost in relation to patients' income
or full health insurance coverage is a key
contributor to rising medication adherence
rate (82).
Direct and indirect costs related to the
treatment regimen and restricted therapy
access are the main reasons leading to self–
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care
management
non–adherence
in
developing countries (83). Other studies
stated that low income patients and/or
without health insurance coverage were more
likely to be medication non–adherent (84,
85). Consequently, copayment pricing set by
the Palestinian Ministry of Health and
subsequent low medications costs on insured
patients might be the main cause for the
limited significant relationship between type
II diabetes costs and medication adherence,
which is considered as a positive point in
favor of the Palestinian governmental health
insurance system.
The study results and others indicated
that good glycemic control has yet to be
achieved in Palestine and Arab region (86).
An inefficient diabetes health care might be
considered as patient and family resources
depletion. Thus, the economic burden has not
yet been translated into optimum diabetes
health care. The univariate analysis on type II
diabetes costs related to good glycemic
control showed a significant relationship
between good glycemic control and direct
costs, both direct medical and non–medical
costs. The multivariate analysis showed that
there were no costs significantly related to
good glycemic control. However, they
deserve attention due to the clarity of these
relationships in multiple studies. Effective
diabetes health care had lower direct cost,
both direct medical and non–medical costs.
This finding is reported to be similar to
another study which reported a relationship
between improved glycemic control and
reduced health care cost (74). Improved
glycemic control is significantly related to
improving overall health status and health
economic benefits (12, 75, 87). Therefore,
the Palestinian Ministry of Health must set
the user fees in the public health care centers
to suit the patients’ income, their treatment
needs, and accompanied by a glycemic
control improvement, which make more
favorable effectiveness/cost ratio. The
impacts of charges policy have not been
studied in Palestine.
The study had four limitations. First, the
sample size is small and follow–up period is
short. However, this study can form a strong
foundation for future studies with a larger
follow–up sample size for a longer duration,
beside other health care system factors.

Second, some patients refused to take part as
consent forms had to be signed, or withdrew
from the study, due to the Palestinian
traditions and customs. So, the researcher had
to convince the participants of the study
importance and their roles in effective study
completion. Third, the researcher put in extra
effort to look for more participants than
planned so as to avoid some participants’
withdrawals. Finally, data collection methods
which were simple, practical, inexpensive,
and most common may be limited by recall
bias, overestimation, healthcare providers
themselves such as incomplete medical
records, and patient–related factors such as
social desirability, and conversation style that
might limit the researcher ability to access an
accurate answer.
CONCLUSIONS
High oral hypoglycemic drugs frequency
was prescribed. Metformin was most
commonly prescribed medications. Most of
the Insulin preparation contains Human
Insulin. More than half of the participants
received 4 to 6 different medications on daily
basis. Prescription pattern should be
reviewed for more rational prescription mode
in line with the patients’ health status. The
study found that health care cost increased as
the medications number increased. A
significantly lower health care cost was seen
in participants receiving ACEI. The patients’
proportion with good glycemic control was
low. Type II diabetes costs were not
significantly related to self–care management
and good glycemic control. However, type II
diabetes costs are worthy to talk about them
as related factors to good glycemic control to
provide a useful platform for further
pharmaco–economic research in Palestine to
put an end of increasing costs and
uninterrupted Insulin supply, whereas the
participants were low income patients.
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